Cytosorbents (CTSO) Total Liabilities (2010 - 2026)

Cytosorbents has reported Total Liabilities for 17 years, with the latest figure at $38.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 5.88% year-over-year to $38.4 million; the trailing twelve-month figure through Mar 2026 stood at $38.4 million (up 5.88% YoY), and the FY2025 full-year result was $38.3 million, up 5.55% from the prior year.
• Total Liabilities for Q1 2026 stood at $38.4 million, roughly flat from $38.3 million in the prior quarter.
• The five-year high for Total Liabilities was $38.4 million in Q1 2026, with the low at $23.1 million in Q3 2022.
• Historically, Total Liabilities has averaged $31.6 million across 5 years, with a median of $29.5 million in 2023.
• The largest YoY upside for Total Liabilities was 172.44% in 2022 against a maximum downside of 5.43% in 2022.
• Cytosorbents' Total Liabilities stood at $27.9 million in 2022, then gained by 5.81% to $29.5 million in 2023, then advanced by 23.04% to $36.3 million in 2024, then rose by 5.55% to $38.3 million in 2025, then rose by 0.23% to $38.4 million in 2026.
• The last three Total Liabilities figures came in at $38.4 million (Q1 2026), $38.3 million (Q4 2025), and $36.7 million (Q3 2025), per Business Quant data.